Premium
Implant treatment in pharmacologically immunosuppressed liver transplant patients: A prospective‐controlled study
Author(s) -
Paredes Víctor,
LópezPintor Rosa María,
Torres Jesús,
Vicente Juan Carlos,
Sanz Mariano,
Hernández Gonzalo
Publication year - 2018
Publication title -
clinical oral implants research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.407
H-Index - 161
eISSN - 1600-0501
pISSN - 0905-7161
DOI - 10.1111/clr.13035
Subject(s) - medicine , implant , contraindication , mucositis , liver transplantation , immunosuppression , prospective cohort study , osseointegration , implant failure , peri implantitis , surgery , dentistry , transplantation , radiation therapy , alternative medicine , pathology
Objectives The main objective of this prospective study was to evaluate the long‐term outcome of implant therapy in liver transplant patients ( LTP ). The secondary goal was to assess several implant‐ and patient‐dependent variables, such as peri‐implantitis ( PI ), peri‐implant mucositis ( PIM ), bone loss (BL), and immediate postoperative complications. Material and methods Two groups, including 16 pharmacologically immunosuppressed LTP and 16 matched controls, received 52 and 54 implants, respectively, between 1999 and 2008. After evaluating the postoperative healing, a mean follow‐up of more than 8 years was carried out, and radiographic, clinical, and periodontal parameters were recorded to evaluate implant survival and implant‐ and patient‐dependent outcomes. Results The early postsurgical complications were similar in both groups. Implant survival rate was 100% in the LTP group and 98.15% in the CG . PIM was diagnosed in 35.42% of the implants and 64.29% of the patients of LTP group ( LTPG ) and in 43.40% of the implants and 56.25% of the patients in the CG . PI was detected in 4.17% of the implants and 7.10% of the patients in the LTPG and in 9.43% of the implants and 18.80% of the patients in the CG . Conclusion Pharmacologically immunosuppression in liver transplant patients was not a risk factor for implant failure, nor for the incidence of peri‐implant diseases. Liver transplant is not a contraindication for dental implant treatment, although these patients should be carefully monitored during follow‐up care.